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Prashanti Vallabhaneni1, Paige Leary1, Benoit Mouzon1,2,3,
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Abstract
No concerted investigation has been conducted to explore overlapping and distinct pathobiological mechanisms between
repetitive mild traumatic brain injury (r-mTBI) and tau/amyloid proteinopathies considering the long history of association
between TBI and Alzheimer’s disease. We address this problem by using unbiased proteomic approaches to generate
detailed time-dependent brain molecular profiles of response to repetitive mTBI in C57BL/6 mice and in mouse models
of amyloidosis (with amyloid precursor protein KM670/671NL (Swedish) and Presenilin 1 M146L mutations [PSAPP]) and
tauopathy (hTau). Brain tissues from animals were collected at different timepoints after injuries (24 hr–12 months post-
injury) and at different ages for tau or amyloid transgenic models (3, 9, and 15 months old), encompassing the pre-, peri-, and
post-“onset” of cognitive and pathological phenotypes. We identified 30 hippocampal and 47 cortical proteins that were
significantly modulated over time in the r-mTBI compared with sham mice. These proteins identified TBI-dependent mod-
ulation of phosphatidylinositol-3-kinase/AKT signaling, protein kinase A signaling, and PPARa/RXRa activation in the hippo-
campus and protein kinase A signaling, gonadotropin-releasing hormone signaling, and B cell receptor signaling in the cortex.
Previously published neuropathological studies of our mTBI model showed a lack of amyloid and tau pathology. In PSAPP
mice, we identified 19 proteins significantly changing in the cortex and only 7 proteins in hTau mice versus wild-type
littermates. When we explored the overlap between our r-mTBI model and the PSAPP/hTau models, a fairly small coinci-
dental change was observed involving only eight significantly regulated proteins. This work suggests a very distinct TBI
neurodegeneration and also that other factors are needed to drive pathologies such as amyloidosis and tauopathy postinjury.
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Mild traumatic brain injury (mTBI) is the most common
(>80% cases) type of TBI within the military and civilian
populations and is a major cause of disability and func-
tional impairment. Epidemiological studies have reported
that individuals exposed to a history of TBI are more
susceptible to developing sporadic age-related neurode-
generative conditions in later life (Gedye et al., 1989;
Mortimer et al., 1991; Fleminger et al., 2003; Li et al.,
2017). The first clues linking TBI with pathological fea-
tures of chronic neurodegenerative disease originated
from studies reporting increased Ab protein in the
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brains of patients who died acutely following TBI or in
excised pericontusional injured tissue (Roberts et al.,
1991, 1994; Ikonomovic et al., 2004; Dekosky et al.,
2007). Neuroimaging studies with the amyloid sensitive
Pittsburgh B compound have confirmed levels of amyloid
beta in the gray matter and striata of TBI survivors com-
parable to mild cognitive impairment patients who go on
to eventually develop dementia (Hong et al., 2014).
A neurodegenerative disorder, chronic traumatic
encephalopathy (CTE), has also been reported, in a pop-
ulation of athletes exposed to repetitive mild TBI
(r-mTBI; Omalu et al., 2011; McKee et al., 2013, 2016).
CTE is marked by perivascular accumulation of phos-
phorylated tau (pTau) at the depths of the sulci.
Although tau has been the major focus of autopsy
cases of CTE, neuritic and diffuse Ab plaques have also
been reported at autopsy in 36% and 52% of CTE cases
(respectively; Stein et al., 2015), and cerebral amyloid
angiopathy has been linked with the pathological and
clinical severity of CTE (Standring et al., 2019).
Neuropathological reports have also shown similarities
in other underlying histopathological features in TBI
brains and age-related neurodegenerative diseases, such
as white matter damage, vascular dysfunction, neuroin-
flammation, astrogliosis, and TDP43 pathology (Van
Den Heuvel et al., 2007; Johnson et al., 2010; Perl,
2010; Omalu et al., 2011; Johnson et al., 2013; McKee
et al., 2013; Smith et al., 2013; McKee et al., 2016), sup-
porting the notion that TBI-induced neurodegeneration
involves multiple pathobiological substrates. However,
the precise nature of how TBI can lead to or precipitate
this path toward tauopathy or amyloidosis remains
elusive.
In-depth characterizations of biochemical cascades in
TBI as it relates to tau and amyloid pathologies have
been precluded by limitations inherent in human studies
such as heterogeneity of TBI etiology, variances in dem-
ographics, lack of controlled prospective studies, and
in vivo detection methods. We have therefore chosen a
preclinical approach, in well-characterized mouse models
of TBI and amyloidosis/tauopathy, for a time-dependent
exploration of the overlap in pathogenic profiles and
sequelae of events following TBI which may reveal how
r-mTBI may lead to or precipitate these pathogenesis.
We have extensively characterized a 5-hit mTBI model
in both wild type and hTau mice, describing the behav-
ioral and histopathological profiles from 24 hr to 24
months postinjury. Injured animals consistently exhibit
persistent deterioration in reconsolidation of spatial
memory and progressive white matter damage typified
by thinning of the corpus callosum, gliosis, and axonal
injury (Mouzon et al., 2012, 2014; Ojo et al., 2015;
Ferguson et al., 2017; Mouzon et al.,2018a, 2018b,
2018c).
Several amyloid- or tau-driven transgenic models
exist, such as the PSAPP and hTau models that represent
amyloid and tau-based pathologies, respectively
(Holcomb et al., 1998; Andorfer et al., 2003). The
PSAPP model (PS1 [M146L], APP [K670N/M671L]) is
a very well established and characterized mouse model of
amyloidosis (Holcomb et al., 1998; Gordon et al., 2002;
Sadowski et al., 2004; Trinchese et al., 2004) that dem-
onstrates progressive age-dependent evolution of
Alzheimer’s disease (AD) pathology accompanied by
gliosis in an accelerated manner compared with single
Tg2576 transgenic mice that carry the APP670/671
(“Swedish”) mutation alone. The hTau mice express all
of the six isoforms of nonmutant human tau and lacks
expression of murine tau (Andorfer et al., 2003). A few
studies have characterized the age-related distribution
and the pathology of hyperphosphorylation and tau
aggregation, and glial activation in these mice, as well
as the cognitive impairment (Duff et al., 2000;
Andorfer et al., 2003; Polydoro et al., 2009).
At the outset of this study, we selected our wild-type
C57BL6 mTBI model and the PSAPP and hTau models
to study the complex molecular pathobiological response
in TBI sequelae and tau/amyloid pathogenesis using an
unbiased proteomics approach previously employed in
our studies (Abdullah et al., 2011; Crawford et al.,
2012; Zakirova et al., 2017; Ojo et al., 2018). During
this longitudinal study, we observed and subsequently
published a series of articles detailing the lack of amyloid
and tau pathology from our neuropathological studies in
our mTBI models up to 24 months postinjury (see
Mouzon et al., 2012, 2014, 2018c). Herein, we use our
proteomic platform to further pursue and explore the
proteomic responses and any overlap or distinction
between these different models.
For both TBI and tau/amyloid transgenic models, we
have generated a comprehensive time line of omic
responses by age or time postinjury, respectively. For
the tau/amyloid transgenic models (hTau and PSAPP),
we chose ages representative of pre-, peri-, and post-
“onset” of the cognitive and pathological phenotypes
(3, 9, and 15 months of age). For our TBI model (using
C57BL/6 mice), we analyzed time intervals from 24 hr to
12 months postinjury, hypothesizing that 12 months
would provide a sufficient postinjury timeframe to cap-
ture molecular signatures to enable comparison with the
age-dependent neurodegenerative pathways observed in
mice demonstrating tauopathy and amyloidosis. Owing
to the lack of chronic amyloid and tau pathology in our
5-hit TBI model in wild-type mice (Mouzon et al., 2012,
2014, 2018c), our goal was not to show a direct TBI-
dependent disease progression to AD in our injured
mice. Thus, we have instead focused on exploring the
distinctions and overlaps in the neurodegenerative path-
ways and sequelae in TBI and our chosen models of
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tauopathy and amyloidosis. We previously published
plasma biomarkers in mice from this same TBI and
tau/amyloid transgenic models (Ojo et al., 2018). We
report our proteomic library of molecular changes from
these studies in the brain following r-mTBI and in the
pathological sequelae of amyloidosis and tauopathy and
present in concert with our neuropathological findings
largely distinct pathways between both models.
Methods
Animals
Wild-type C57BL/6 controls and hTau mice (Andorfer
et al., 2003) were purchased from the Jackson
Laboratories (Bar Harbor, ME). PSAPP mice expressing
the double “Swedish” mutation in APP and the M146L
mutation in PS1 were bred onto a C57BL/6 background
in our vivarium. Their littermate controls were used as
the wild-type controls. For the r-mTBI cohort, C57BL/6
mice (from Jackson Laboratories) were used. All the mice
used in this study were male. All mice in the models of
amyloidosis and tauopathy were aged until euthanasia at
3, 9, or 15 months, intended to represent ages pre-, peri-,
and postonset of amyloidogenesis and tau pathology.
For our r-mTBI study, mice were 3 months old at the
time of their injury or sham injury and were euthanized
at 24 hr, 3, 6, 9, or 12 months postinjury/sham. We have
used exactly the same TBI and tau/amyloid transgenic
mice and their chosen timepoints of evaluation from
our previous article exploring blood proteomic bio-
markers in TBI and models of amyloidosis and tauop-
athy (Figure 1). Please refer to our previous article for
information on animal housing and conditions (Ojo
et al., 2018). Proteomic analyses of r-mTBI mice were
conducted in the hippocampus and cortex, while analyses
of PSAPP/C57BL/6J and hTau/C57BL/6J mice were
conducted in the cortex. Mice (N¼ 4/group) were
assigned randomly to their groups, and all our analyses
were designed blind to the experimenter. Studies per-
formed herein were performed under a protocol
approved by the Roskamp Institute Institutional
Animal Care and Use Committee (IACUC - R054). All
studies were in keeping with the Office of Laboratory
Animal Welfare and National Institutes of Health
guidelines.
Experimental mTBI
Our experimental closed head injury paradigm followed
procedures previously described (Mouzon et al., 2012).
Procedures have been described in detail in Ojo et al.,
2018. Briefly, we anesthetized sham/injury mice for
3min with 1.5 L/min of oxygen and 3% isoflurane. We
shaved the head of mice and placed them on a stereotaxic
frame (Just For Mice Stereotaxic, Stoelting, Wood Dale,
IL) that was mounted with an electromagnetic controlled
impact device (Impact One Stereotaxic Motorized
Impactor, Richmond, IL). Their body temperature was
maintained at 37C on a heating pad. A flat and blunt
5-mm metal impactor tip mounted onto the electromag-
netic motorized device was zeroed on the shaved scalp,
positioned above the midsagittal suture. After position-
ing, the metal tip was retracted and adjusted to a 1-mm
depth strike. Scalp of mice were stretched to avoid deliv-
ering a trauma load that was inadequate and at an irreg-
ular angle. Parameters of injury were 5m/s velocity,
depth of 1.0 mm, 200 ms dwell time, and a projected
72 N strike force. This impact is sublethal; no skull frac-
tures or subdural hemorrhages have been observed with
our injury paradigm. r-mTBI mice were exposed to 5 hits
over 9 days, with a 48-hr interinjury interval. r-sham mice
were exposed to 3min of anesthesia of the same frequen-
cy (5). After injury, mice were placed on a 37C heating
pad before return to their normal cages.
Proteomics Experiments
Subcellular Protein Extraction From Brain Homogenates. Snap
frozen brain tissues were weighed and homogenized in
liquid chromatography and mass spectrometry
Figure 1. Proteomic Study Design and Time Lines of r-mTBI and
Models of Amyloidosis and Tauopathy. This study used six groups of
mice. The r-sham/r-mTBI group consisted of C57BL/6J mice at 3
months old, with euthanasia at 24 hr, 3, 6, 9, and 12 months post-
TBI. Tauopathy group involved of hTau / C57BL/6J background
strain mice with euthanasia at 3, 9, and 15 months old. Amyloidosis
group involved PSAPP / C57BL/6J littermate mice with euthanasia
at 3, 9, and 15 months old.
r-mTBI¼ repetitive mild traumatic brain injury.
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(LC-MS) grade chilled water at a volume of 2.5 (corti-
ces) and 4.5 (hippocampi) wet weight, respectively.
Fifty microliters of homogenates were added to a 50-ml
aqueous buffer solution containing 2 phosphate-
buffered saline, 2 sodium chloride, and proteinase
inhibitor (ThermoScientific, Waltham, MA). Samples in
aqueous buffer were further homogenized with a probe
sonicator and underwent centrifugation at 20,000g for
15min at 4C. Supernatant (nonmembrane fraction)
was collected in a different Eppendorf tube to obtain
cytosolic and nuclear protein fractions. Pelleted samples
were resuspended in an aqueous solution containing 1
volume of ice-cold methanol (ThermoScientific,
Waltham, MA) and 20,000g centrifugation for 15min
at 4C. The precipitant was further resuspended in a
1 volume of ice-cold isopropanol and hexane
(ThermoScientific, Waltham, MA) at a 2:1 dilution, fol-
lowed by centrifugation at 20,000g for 15min, and mem-
brane protein pellet fractions were resuspended in 25 mM
tetraethylammonium bromide (TEAB – Sigma-Aldrich,
St Louis, MO) and 0.5% sodium deoxycholate (SDC –
Sigma-Aldrich, St Louis, MO). Original supernatants
(nonmembrane fractions) from the first centrifugation
step were brought up in 0.5 volume of ice-cold metha-
nol and centrifuged at 20,000g for 15min, and the nucle-
ar protein pellet fractions were resuspended in 25 mM
TEAB and 0.5% SDC. Supernatant fractions from the
last step was brought up in 7 volume of ice-cold meth-
anol and centrifuged at 20,000g for 15min, and cytosolic
protein pellets were resuspended in 25 mM TEAB and
0.5% SDC. Membrane and cytosolic protein extracts
were used in the entire study.
Trypsin Digestion. We added sequencing grade porcine
trypsin (Promega, Fitchburg, WI) to aliquots from the
hippocampus (50 mg) or cortex (100 mg), respectively (at a
final protein concentration of 1 mg/ml), of depleted brain
homogenate at an enzyme-to-substrate ratio of 1:100,
followed by incubation at 37C for 16 hr. Then, 10 ml
of samples were taken to dryness in a vacuum centrifuge
for labeling with tandem mass isobaric tags.
Tandem Mass Tag Labeling. To accommodate all timepoints/
aged from all genotypes and sham/injury groups to be
analyzed within the same batch, we used a multiplex
tandem mass tag (TMT) kit. This enabled randomization
of samples from all the different groups to be analyzed in
the same batch with the inclusion of an internal reference
per batch. Briefly, 6- and 10-plex TMT labeling kits
(ThermoScientific, Waltham, MA) were used for analyses
of samples from tau/amyloid transgenic (at 3, 9, 15 months
of age) and sham/injury mice (24 hr, 3, 6, 9, 12 months
postinjury), respectively. TMT labeling procedures have
been previously described (see Ojo et al., 2018 for details).
Sample IDs for each isobaric label tags were unknown to
the experimenter. Labeled samples were taken to dryness in
a vacuum centrifuge to remove acetonitrile before the
SDC/TEAB cleanup procedure.
SDC–TEAB Cleanup. SDC/TEAB was removed from the
dried TMT-labeled pooled samples using the steps
described later. Dried samples were resuspended in 1%
formic acid diluted in LC-MS grade water (at 100 ml) and
centrifuged (20,000 g RCF) for 1min to remove precip-
itated SDC. Supernatant was collected, and 400 ml of
ethyl acetate (ThermoScientific, Waltham, MA) was
added. Samples were subsequently vortexed and centri-
fuged (at 20,000g) for 30 s to partition residual SDC into
the upper (organic) layer; the resultant upper layers were
discarded. This was repeated three more times, with the
final lower phase taken to dryness and resuspended in
0.1% formic acid (Sigma-Aldrich, St Louis, MO) diluted
in (100 ml) LC-MS grade water (ThermoScientific,
Waltham, MA). Samples were then subsequently concen-
trated and desalted using C18 reversed phase ZipTips
(MilliporeSigma, Burlington, MA) based on the manu-
facturer’s protocol. Eluates from the ZipTip procedure
were resuspended in 0.1% formic acid (20 ml) and trans-
ferred into an autosampler vial, for analysis using a
nano-UPLC MS on a Q-Exactive Orbitrap instrument
(ThermoScientific, Waltham, MA).
Chromatography and Mass Spectrometry Methods
(LC-MS/MS)
An LC-MS/MS (Q-Exactive) was used to analyze all
samples in this experiment. Data-dependent acquisition
settings for the experiments have been previously
described in our earlier proteomic study (see Ojo et al.,
2018 for more details). Our rationale for selecting these
settings, especially our narrow isolation window com-
bined with the ultra-long gradient, was to essentially min-
imize deleterious effects on quantitative accuracy that
may result from coisolation of isobaric precursors with-
out resorting to MS3-based methods.
Data Processing and Statistical Analysis. The animals were
randomly assigned to multiplexes and the labels and ana-
lyzed blindly to prevent any unwanted experimental bias.
We used the PMi Preview software to survey data files
and add additional modifications to our search criteria.
Preview results were also used to choose precursor/frag-
ment ion mass tolerances (4 ppm, 0.02 Da, respectively)
including dynamic modifications. Settings used to search
the data using SEQUEST and MSAMANDA as the
searches algorithms have been previously described
(Ojo et al., 2018). We considered only unique peptides
for quantification purposes. A false discovery rate
(FDR) of 0.01 was set, with resulting datasets exported
to JMP 8.0.2 (Cary, NY) for our statistical analysis.
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FDR of 0.01 is the default “stringent” setting in the pro-
teome discoverer analytical software; it is common to use
this stringent level of FDR for peptides, which considers
that out of every 100 peptides identified 1 may not be
real. We used only proteins found in at least 50% of the
total number of plexes for our quantitative analysis. Data
from raw ion counts were ln transformed,
with each channel normalized using central tendency
normalization method, whereby the medians were
used. Ratios were generated by dividing datasets
from each timepoint (3month [3 m], 6month [6 m],
9month [9 m], or 12month [12 m]) with 24 hr timepoint
within the TBI and sham group separately per plex.
Likewise for the study involving models of
amyloidosis and tauopathy we divided data from each
age-group (9month [9 m], 15month [15 m]) with
3month [3 m] of age within the PSAPP and C57BL6
group separately per plex. Peptides that were not quan-
tified in at least eight runs were omitted from the analy-
sis. We used the mixed model analysis of variance
(ANOVA) for analyses. The following linear model (1)
was used per injury/genotype in animal models:
yijklmn ¼ lþ aiþ bjþ ck jð Þ þ dlþ pm þ eijklm (1)
where l is the population mean; ai: random variable
mouse pair NID(0,r2b); bj: random variable protein
incomplete block NID(0, r2b); ck(j): random variable
peptide incomplete block NID(0, r2c); dl: fixed variable
time type NID; pm: random variable TMT plex no.
(0,r2p); and eijklm: random variable error in our experi-
ment NID(0, r2e). We used a Benjamini and Hochberg
FDR multiple testing correction method, for most strin-
gent analyses, to select a “top tier” of significantly regu-
lated proteins, and thus eliminate false positives. The MS
data have been placed in the Proteome-Xchange
Consortium (Deutsch et al., 2016) using the PRIDE part-
ner repository (dataset identifiers include PXD010664
and PXD010602). For access to PXD010664, username:
reviewer60134@ebi.ac.uk and password: ma0JJzM9. For
access to PXD010602, username: reviewer32616@ebi.ac.
uk and password: XcERUSTV.
Analytical Approach. The dataset was analyzed using two
different approaches. Our first approach was to divide
values from each of the TBI animals with a randomly
matched sham animal at a given timepoint to measure the
response to TBI at each timepoint. However, because each
TBI animal was being directly compared with a random
sham animal instead of all TBI or sham animals being com-
pared with a single reference animal, statistical noise was
introduced to the data. Moreover, this type of ratio (TBI/
sham), can only be analyzed using a method that tests if the
ratio is significantly different from 0 (as the data is ln
transformed). There were either no, or very small number
of, proteins that were changing due to TBI using this statis-
tical analysis approach. To reduce statistical noise and
increase the power, the 24 hr timepoint was chosen as ref-
erence, and TBI and sham animals were analyzed separately
using the mixed model ANOVA method that is more pow-
erful than a one-sample t test. These identified proteins that
were changing over time in the r-mTBI and the r-sham
groups enabling upload of these lists to the ingenuity path-
way analysis (IPA) software (Qiagen IPA, Redwood City,
CA) where molecules and pathways responding over time
could be identified along with differences between r-mTBI
and r-sham. We confirmed the validity of this approach
(using a reference sample) in other proteomic experiments
where transgenic mouse models were used and significant
protein lists included the transgene product. To be consis-
tent with this type of analytical approach, we have also
presented the PSAPP/C57BL6 and hTau/C57BL6 studies
in a similar manner, as we also observed statistical noise
in the direct comparisons of transgenic versus wild-type
mice. Thus, we use the 3M of age mice as a reference,
with the 9M and 15M datasets from PSAPP/C57BL6 litter-
mates, hTau/C57BL6 animals expressed as a ratio of their
3M dataset. Each of the four groups was analyzed separate-
ly using the mixed model ANOVA method and significantly
identified proteins uploaded into the IPA software to iden-
tify how age-dependent changes in molecules and pathways
were influenced by the hTau or PSAPP transgene.
IPA Analysis
The three datasets of significantly modulated proteins
(r-mTBI/sham, hTau/C57BL6, PSAPP/C57BL6 litter-
mates) were uploaded to the IPA software (IngenuityVR
Systems) to enable us to map proteins to established net-
works of protein interactions to determine the functional
significance of hTau/amyloid/r-mTBI-dependent changes
in protein expression from our studies. The core analysis
settings for IPA analyses of uploaded significantly regu-
lated proteins used the same procedures described in Ojo
et al., 2018 to assign them onto established molecular
pathways (“canonical pathways”) and biological func-
tions in the knowledge base.
Enzyme-Linked Immunosorbent Assay
Validation of proteins was conducted by using enzyme-
linked immunosorbent assay (ELISA). Details of proce-
dures for each ELISA kit (given later) is described in the
manufacturers guidelines: (a) myristoylated alanine-rich
protein kinase C substrate (My BioSource; MBS2890340
– San Diego, CA); (b) SLC1A2/EAAT2/GLT-1—excit-
atory amino acid transporter 2 (LifeSpan BioSciences;
LS-F6561 – Seattle, WA); (c) protein tyrosine
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phosphatase, nonreceptor type 23 (My BioSource;
MBS9332331 – San Diego, CA).
Results
Time-Dependent Changes in Unique and Common
Proteins in the Hippocampus of Sham and r-mTBI
Mice Across Multiple Timepoints
A 10-plex TMT isobaric tag approach was used to study
the protein profiles in the hippocampus of r-sham and
injured mice at five separate timepoints postinjury (24 hr,
3, 6, 9, and 12 months; see Figure 2).
Our MS/MS-based proteomics analyses generated
protein identities based on identified peptides, and to
avoid redundancy, proteins within a group were ranked
based on the number of peptide sequences, the number of
peptide spectrum matches, their protein scores, and the
sequence homology/coverage, with the top-ranking pro-
tein being identified as a master protein based on this
criteria. A total of 729 nonredundant master protein
were identified in the hippocampus in this study, 170 of
these were identified within all plexes and groups
examined.
We normalized samples from each timepoint to their
24 hr post-TBI or sham group, and analyses using
mixed model ANOVA and after Benjamini-Hochberg
correction identified 17 unique proteins significantly
changing over time in sham injured mice, 30 unique
proteins significantly changing in repetitive injured
mice, and 76 common proteins significantly changing
in both sham and injury groups over time (Figure 2;
see also Supplementary Figure S1 for list of significant
proteins in sham group and Supplementary Figure S2
for list of significant proteins in the injury group). A list
of the unique significantly modulated proteins observed
Figure 2. Tandem Mass Tag (TMT) Labeling, Liquid Chromatography-Mass Spectrometry, and Workflow for Proteomic Analyses From
r-mTBI and r-sham Mice. Workflow shows randomization of both hippocampal and cortical samples for TMT multiplexing. Samples were
pooled for multiplexing with 10-plex TMT isobaric mass tag labels. Workflow shows total number of nonredundant master protein groups,
master proteins identified and analyzed, and Venn diagram depicting significantly proteins changing over the five multiple postinjury
timepoints from sham/TBI mice. In the hippocampus, 17 unique proteins were significantly changing in shams, 30 unique proteins were
changing in injured mice, and 76 proteins were common in sham and TBI mice. In the cortex, 32 unique proteins were significantly changing
in sham mice, 47 unique proteins were changing in injured mice, and 69 were common in sham and TBI mice.
TMT¼ tandem mass tag; LC/MS¼ liquid chromatography and mass spectrometry; ANOVA¼ analysis of variance; r-mTBI¼ repetitive mild
traumatic brain injury.
6 ASN Neuro
across multiple timepoints in the injury group is shown
in Table 1.
Biofunctions, Canonical Pathways, and Pathobiological
Processes Modulated in the Hippocampus Samples
From r-mTBI and r-Sham Mice Across Multiple
Timepoints
IPA generated a list of 16 biofunctions and pathobiolog-
ical processes modulated in the hippocampus of
r-mTBI versus sham injury groups across multiple time-
points, and this is shown in Figure 3. Some of the
diseases/biofunctions include exocytosis, engulfment of
cells, neurodegeneration, synaptic depression, and
formation of vesicles. IPA identified the top three signif-
icantly modulated canonical pathways generated from
our list of significantly regulated proteins in the
hippocampus of injured versus sham groups. These path-
ways include phosphatidylinositol-3-kinase (PI3K)/AKT
signaling, protein kinase A signaling, and Peroxisome
proliferator-activated receptor alpha and Retinoid X
receptor alpha (PPARa/RXRa) activation (see Figure 4).
Time-Dependent Changes in Unique and Common
Proteins in the Cortices of r-mTBI and r-Sham Mice
Across Multiple Timepoints
A 10-plex TMT isobaric tag approach was used to study
the profiles in the cortices of r-TBI and sham mice at five
timepoints postinjury (24 hr, 3, 6, 9, and 12 months; see
Figure 2). In this study, a total of 1,277 nonredundant
master protein groups were identified in the cortex, and
343 of these master protein groups were identified within
all plexes and groups. As mentioned earlier, a mixed
Table 1. List of Unique Significantly Modulated (30) Proteins From the Hippocampus of Repetitive mTBI Mice, Compared With Their
Sham Counterparts Across Multiple Timepoints.
List of unique proteins longitudinally modulated in the hippocampus of r-mTBI mice    REPETITIVE MTBI 
M.P.A  DESCRIPTION P Value 3M 6M 9M 
P68510 14-3-3 protein eta 0.028 
P68254 14-3-3 protein theta (14-3-3 protein tau) 0.003 
P63101 14-3-3 protein zeta/delta (Protein kinase C inhibitor protein 1)  0.002 
P16330 2',3'-cyclic-nucleode 3'-phosphodiesterase (CNPase) 0.000 
P61205 ADP-ribosylaon factor 3 0.045 
P16546 Alpha-II spectrin 0.009 
Q9CPQ8 ATP synthase subunit g, mitochondrial 0.015 
Q9DB20 ATP synthase subunit O, mitochondrial  0.041 
A8DUK4 Beta-globin  0.005 
Q8BH59 Calcium-binding mitochondrial carrier protein Aralar1  0.000 
P28652 CaM kinase II subunit beta 0.009 
Q9Z1G4 Clathrin-coated vesicle/synapc vesicle proton pump 116 kDa subunit 0.014 
P12960 Contacn-1  0.008 
Q9D0M3 Cytochrome c1, heme protein, mitochondrial (Complex III subunit 4)  0.011 
P05063 Fructose-bisphosphate aldolase C  0.010 
P15105 Glutamine synthetase  0.005 
P26883 Immunophilin FKBP12 0.016 
P16125 L-lactate dehydrogenase B chain (LDH-B) 0.022 
Q9CR62 Mitochondrial 2-oxoglutarate/malate carrier protein (OGCP) 0.023 
Q91YT0 NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial  0.018 
Q9DCT2 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial 0.019 
P13595 Neural cell adhesion molecule 1  0.045 
Q80TL4 PHD finger protein 24 0.045 
Q61644 Protein kinase C and casein kinase substrate in neurons protein 1 (Syndapin-1) 0.018 
Q9D051 Pyruvate dehydrogenase E1 component subunit beta, mitochondrial 0.005 
Q8BWF0 Succinate-semialdehyde dehydrogenase, mitochondrial  0.011 
Q61548 Synaptosomal-associated protein 91 (Snap91) 0.029 
P61264 Syntaxin-1B 0.044 
Q3TXX4 Vesicular glutamate transporter 1 (VGluT1) 0.000 
Q60930 Voltage-dependent anion-selecve channel protein 2 (VDAC-2) 0.031 
12M 
Note. p value denotes FDR-adjusted p value following mixed model ANOVA and Benjamini-Hochberg correction. Heat map depicts upregulated levels in
blue and downregulated levels in red. Similarly, red and blue text depicts proteins downregulated and upregulated across multiple time points. MPA¼master
protein accessions; r-mTBI¼ repetitive mild traumatic brain injury.
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Figure 3. Biofunctions and Disease Altered in the Hippocampus of Sham/Injury Mice. Biofunctions and diseases identified from the list of
generated significant proteins in sham/injury groups over multiple timepoints using ingenuity pathway analyses (IPA).
mTBI¼mild traumatic brain injury.
Figure 4. Canonical Pathways Altered in the Hippocampus of Sham/Injury Mice. Canonical pathways generated from the list of generated
significant proteins in sham/injury groups over multiple timepoints using IPA. Top three pathways include PI3K/AKT signaling, protein
kinase A (PKA) signaling, and PPARa/RXRa activation.
mTBI¼mild traumatic brain injury; PI3K¼ phosphatidylinositol-3-kinase.
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model ANOVA approach was used to analyze the master
proteins present in all plexes to identify prospective
changes in unique and common proteins between sham
and TBI groups over multiple timepoints.
Samples were once again normalized with their 24 hr
postinjury/sham group, and analyses of age-related
changes within injured and sham groups using
mixed model ANOVA after Benjamini-Hochberg
correction identified 32 unique proteins changing in the
sham group, 47 unique proteins changing in the
repetitive injured group, and 69 common proteins chang-
ing in both sham and injury groups over time (Figure 2;
see also Supplementary Figure S3 and S4 for list of pro-
teins). A list of the significantly regulated proteins
uniquely changing in the injured group is shown in
Table 2.
To validate our proteomics LC-MS/MS results, we
used an antibody-based approach to examine the levels
of three proteins in cortical tissue (myristoylated alanine-
rich protein kinase C substrate; protein tyrosine phos-
phatase, nonreceptor type 23, and excitatory amino
acid transporter 2). These proteins were chosen on the
basis that they were highly abundant in our samples, sig-
nificantly regulated in sham and/or TBI, and also easily
detectable by a reputable and well-established antibody-
based (ELISA) method. These three proteins showed
trends consistent with our TMT data at four separate
timepoints investigated in the groups specifically ana-
lyzed (Supplementary Figure 5). We also measured
levels of heat shock protein 90 (HSP 90) by ELISA
method (data not shown). Our results showed statistically
similar trends between TMT and ELISA methods; how-
ever, the direction of change was observed in opposite
directions, with a reduction observed by TMT analyses
and an increase by ELISA over time.
Biofunctions, Canonical Pathways, and Pathobiological
Processes Modulated in the Cortical Samples From
r-mTBI and r-Sham Mice Across Multiple Timepoints
A list of 37 biofunctions and pathobiological processes
modulated in the cortices of r-mTBI versus sham groups
across multiple timepoints is shown in Figure 5.
Some of these include endocytosis, myelination, neuro-
degeneration of axons, engulfment of cells, migration of
neuroglia, clathrin-mediated endocytosis, axonogenesis,
and receptor-mediated endocytosis. Ingenuity pathway
analyses (IPA) identified the top three canonical path-
ways significantly regulated within the cortex of TBI
versus sham groups after analyses of significantly modu-
lated proteins. These pathways include protein kinase A
signaling, protein gonadotropin-releasing hormone
(GnRH) signaling, and B cell receptor activation (see
Figure 6).
Time-Dependent Changes in Unique and
Common Proteins in the Cortex of hTau and
PSAPP Mice at Different Ages
We used a 6-plex TMT isobaric tag multiplex approach
to study the profiles between hTau mice versus C57BL6
wild-type mice and PSAPP versus C57BL6 wild-type lit-
termate mice at 3 different ages (3, 9, and 15 months; see
Figure 7).
A total of 1,408 and 893 nonredundant master protein
groups were identified from the PSAPP and hTau study,
respectively; 399 identified master protein groups were
present in all plexes and groups of the PSAPP study
and 226 in the hTau study (Figure 7).
Dataset were analyzed separately using the mixed
model ANOVA after Benjamini-Hochberg correction to
identify proteins changing with age in the two transgenic
and respective wild-type groups.
In the PSAPP group, 19 proteins were significantly
changing with genotype alone, and 6 proteins were iden-
tified that showed a significant interaction between geno-
type and aging (Figure 7). In the hTau group, seven
proteins were significantly changing with genotype
alone, and four proteins were identified that showed
significant interaction between genotype and aging
(Figure 7). A list of genotype-specific age-related signifi-
cantly regulated proteins in the cortices of PSAPP versus
wild-type groups and hTau versus wild-type groups is
shown in Tables 3 and 4, respectively. Unfortunately,
analyses of the hippocampal samples from these
mice were not possible because they were processed dif-
ferently from TBI samples and also used for lipidomic
analyses.
Commonalities Between r-mTBI Model and
hTau/PSAPP Models
To investigate any potential molecular pathobiological
relationship underlying the sequelae of events in TBI
and models of amyloidosis and tauopathy, we compared
using mixed model ANOVA the significant cortical pro-
teomic profiles that were uniquely r-mTBI dependent or
either PSAPP or hTau dependent (Figure 8). Only six
proteins were common to the r-mTBI mouse model and
the PSAPP mouse model (ADP/ATP translocase 2,
CAMKII, hemoglobin subunit a, hexokinase-1,
NADH-ubiquinone oxidoreductase, and spectrin alpha
chain, nonerythrocytic 1; see Table 3 and Figure 8),
while only two were common to the r-mTBI model and
the hTau mouse model (alpha-internexin and neural cell
adhesion molecule 1; see Table 4 and Figure 8). A sum-
mary of the proteomic and altered biofunctions observed
in all three models is detailed in Figure 9.
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Discussion
Our previous neuropathological assessment of our 5-hit
r-mTBI model revealed a lack of tau or amyloid pathol-
ogy up to 24 months postinjury. Thus, in this work, we
aimed to use our proteomic platform to further explore
the underlying molecular responses to r-mTBI in our
mouse model (Mouzon et al., 2012; Ojo et al., 2013;
Mouzon et al., 2014; Ojo et al., 2015), with two unique
preclinical models of amyloidosis (PSAPP) and tauop-
athy (hTau). We employed an unbiased LC-MS/MS-
based approach and have generated a detailed time line
of molecular responses in the cortex and hippocampus
from 24 hr to 12 months postinjury in mouse models of
r-mTBI and in transgenic mouse models of amyloidosis
Table 2. List of Unique Significantly Modulated (47) Proteins From the Cortex of Repetitive mTBI Mice, Compared With Their Sham
Counterparts Across Multiple Timepoints.
M.P.A DESCRIPTION P Value 3M 6M 9M 12M 3M 6M 9M 12M 
Q64433 10 kDa heat shock protein, mitochondrial 0.016 
Q9CR95 NECAP endocytosis-associated protein 1 0.025 
P50247 Adenosylhomocysteinase  0.043 
P51881 ADP/ATP translocase 2  0.000 
P46660 Alpha-internexin  0.003 
Q7TQF7 Amphiphysin 0.048 
Q9CPQ8 ATP synthase subunit g, mitochondrial  0.024 
Q8R016 Bleomycin hydrolase 0.038 
P28652 CAMKII 0.038 
Q91WS0 CDGSH iron-sulfur domain-containing protein 1  0.012 
P18760 Cofilin-1  0.040 
P84086 Complexin-2  0.006 
P12960 Contacn-1 0.000 
Q9CZ13 Cytochrome b-c1 complex subunit 1, mitochondrial  0.020 
P00405 Cytochrome c oxidase subunit 2  0.013 
Q62108 Disks large homolog 4  0.040 
P26443 Glutamate dehydrogenase 1, mitochondrial  0.007 
Q61316 Heat shock 70 kDa protein 4  0.001 
P63017 Heat shock cognate 71 kDa protein  0.000 
P07901 Heat shock protein HSP 90-alpha  0.011 
P01942 Hemoglobin subunit alpha  0.000 
P17710 Hexokinase-1  0.000 
Q9D6R2 Isocitrate dehydrogenase [NAD] , mitochondrial 0.007 
P26645 Myristoylated alanine-rich C-kinase substrate  0.043 
Q91VD9 NADH-ubiquinone oxidoreductase 75kDa  0.013 
P13595 Neural cell adhesion molecule 1  0.013 
Q9Z1S5 Neuronal-specific sepn-3  0.007 
P09405 Nucleolin 0.040 
Q9D0F9 Phosphoglucomutase-1  0.000 
P09411 Phosphoglycerate kinase 1  0.006 
Q99K85 Phosphoserine aminotransferase  0.016 
P63001 Ras-related C3 botulinum toxin substrate 1  0.004 
Q99P72 Reculon-4  0.041 
Q91V61 Sideroflexin-3  0.037 
P31650 Sodium- and chloride-dependent GABA transporter 3  0.044 
Q62261 Spectrin beta chain, non-erythrocyc 1  0.010 
Q8R191 Synaptogyrin-3  0.028 
O08599 Syntaxin-binding protein 1  0.000 
Q62283 Tetraspanin-7  0.030 
Q9D6F9 Tubulin beta-4A chain  0.000 
P99024 Tubulin beta-5 chain  0.001 
Q6PB44 Tyrosine-protein phosphatase non-receptor type 23  0.029 
D3YWG1 Uncharacterized protein  0.044 
Q9Z1G4 V-type proton ATPase 116 kDa subunit a isoform 1  0.000 
P51863 V-type proton ATPase subunit d 1  0.020 
P50518 V-type proton ATPase subunit E 1  0.001 
Q3TXX4 Vesicular glutamate transporter 1  0.038 
REPETITIVE SHAM REPETITIVE MTBI List of unique proteins longitudinally modulated in the cortex of r-mTBI mice
Note. p value denotes FDR-adjusted p value after mixed model ANOVA and Benjamini-Hochberg correction. Heat map depicts upregulated levels in blue and
downregulated levels in red. MPA¼master protein accessions; r-mTBI¼ repetitive mild traumatic brain injury.
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Figure 5. Biofunctions and Disease Altered in the Cortex of Sham/Injury Mice. Biofunctions and diseases identified from the list of
generated significant proteins in sham/injury groups over multiple timepoints using ingenuity pathway analyses (IPA).
mTBI¼mild traumatic brain injury.
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Figure 6. Canonical Pathways Altered in the Cortex of Sham/Injury Mice. Canonical pathways generated from the list of generated
significant proteins in sham/injury groups over multiple timepoints using IPA. Top three pathways include protein kinase A (PKA) signaling,
GnRH signaling, and B cell receptor signaling.
mTBI¼mild traumatic brain injury; GnRH¼ gonadotropin-releasing hormone.
Figure 7. Tandem Mass Tag (TMT) Labeling, Liquid Chromatography-Mass Spectrometry, and Workflow for Proteomic Analyses in hTau
and PSAPP Mice. Workflow shows randomization of cortical samples for TMT multiplexing. Samples were pooled for multiplexing with
6-plex TMT isobaric mass tag labels. Workflow shows total number of nonredundant master protein groups, master proteins identified and
analyzed, and Venn diagram depicting significantly proteins changing over the 3 age groups in hTau and PSAPP mice. In PSAPP mice,
19 proteins were significantly changing with genotype (PSAPP vs. wild type), and 6 proteins showed significant interaction with aging and
genotype. In the hTau group, seven proteins were significantly regulated with genotype (hTau vs. wild type), and four proteins showed
significant interaction with aging and genotype.
TMT¼ tandem mass tag; LC/MS¼ liquid chromatography and mass spectrometry; ANOVA¼ analysis of variance.
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and tauopathy encompassing pre-, peri-, and post-
“onset” of pathological phenotypes (3 to 15 months of
age). Our data reveal largely distinct r-mTBI-dependent
and tau/amyloid-driven and dependent molecular-level
changes which are of interest to the chronic consequences
of r-mTBI in humans.
Proteomic Changes in the Hippocampus and Cortex
Following r-mTBI
Our prior work with this wild-type 5-hit r-mTBI model
have been previously published and demonstrates defi-
ciency in hippocampal-dependent spatial learning and
memory processing (Barnes Maze) at 24 hr postinjury,
which persists until 6 months, and progressively wor-
sens at 12, 18, and 24 months postinjury timepoints
(Mouzon et al., 2012, 2014, 2018c). We have also
extensively characterized the histopathological features
of this model at 24 hr, 3, 6, 12, and 24 months post-
injury; injured animals consistently demonstrate persis-
tent white matter damage involving thinning of the
corpus callosum, gliosis, and axonal injury (Mouzon
et al., 2012, 2014; Ojo et al., 2015; Ferguson et al.,
2017; Mouzon et al., 2018a, 2018b, 2018c). However,
gross neuropathological assessment of the gray matter
(hippocampus and also cortex) revealed no overt signs
of proteinaceous (tau, amyloid, etc.) lesions resulting
from the chronic effects of injury. Injury-dependent
astroglial and microglial activation, transient increase
in phospho-tau levels, ultrastructural abnormalities to
dendrites, and electron dense dark neurons, although
observed at earlier timepoints (either 24 hr or 3
months) postinjury, were not observed beyond >6 to
24 months after injury in the gray matter (Mouzon
Table 3. List of Significantly Modulated Proteins From the Cortex of PSAPP Mice Compared With Wild-Type Controls.
 WILDTYPE MICE    PSAPP MICE 
M.P.A Descripon P Value 9 Mos 15 Mos 9 Mos 15 Mos 
P16330 2',3'-cyclic-nucleode 3'-phosphodiesterase  0.0001 0.23 0.29 0.14 0.12 
Q99KI0 Aconitate hydratase, mitochondrial  0.0063 -0.06 0.03 0.11 0.10 
P51881 ADP/ATP translocase 2  0.0270 -0.07 -0.01 0.06 0.08 
Q03265 ATP synthase subunit alpha, mitochondrial  0.0489 -0.07 0.02 0.05 0.02 
Q9DB20 ATP synthase subunit O, mitochondrial  0.0346 -0.17 -0.11 -0.03 -0.01 
A8DUK4 Beta-globin OS=Mus musculus  0.0000 0.29 0.93 -0.11 -0.46 
Q8BH59 Calcium-binding mitochondrial carrier protein Aralar1  0.0159 -0.12 0.02 0.08 0.05 
P11798 CAMKII 0.0063 -0.14 -0.08 -0.23 -0.16 
Q9DB77 Cytochrome b-c1 complex subunit 2, mitochondrial  0.0001 -0.11 -0.05 0.04 0.02 
Q9CQ69 Cytochrome b-c1 complex subunit 8  0.0037 -0.25 -0.20 -0.01 0.02 
P05063 Fructose-bisphosphate aldolase C  0.0306 0.02 -0.07 0.10 0.17 
P16858 Glyceraldehyde-3-phosphate dehydrogenase  0.0474 -0.19 0.41 0.34 0.31 
Q64521 Glycerol-3-phosphate dehydrogenase, mitochondrial  0.0473 -0.07 0.04 0.09 0.16 
P18872 Guanine nucleode-binding protein G(o) subunit alpha  0.0000 0.18 0.20 0.00 -0.09 
P01942 Hemoglobin subunit alpha  0.0131 0.41 1.13 -0.21 -0.46 
P17710 Hexokinase-1  0.0170 -0.20 -0.05 -0.03 -0.05 
P05067-4 Isoform APP695 of Amyloid beta A4 protein  0.0000 -0.25 -0.12 2.65 3.92 
Q91VD9 NADH-ubiquinone oxidoreductase 75 kDa   0.0306 -0.05 0.05 0.10 0.07 
O08709 Peroxiredoxin-6 OS=Mus musculus  0.0155 -0.04 -0.02 0.09 0.21 
P16546 Spectrin alpha chain, non-erythrocyc 1  0.0000 0.00 -0.19 -0.15 -0.07 
P54227 Stathmin  0.0159 -0.01 -0.32 -0.20 0.03 
Q8BWF0 Succinate-semialdehyde dehydrogenase, mitochondrial  0.0251 0.11 0.14 -0.03 -0.05 
P68369 Tubulin alpha-1A chain  0.0306 -0.02 -0.11 -0.24 -0.17 
P46460 Vesicle-fusing ATPase  0.0155 -0.09 -0.08 -0.20 -0.26 
Q60930 Voltage-dependent anion-selecve channel protein 2  0.0270 -0.20 -0.15 0.00 0.01 
Note. Data depict least squared mean values generated after logarithmic transformation of normalization abundance ratio data from each genotype group.
p value represents FDR-adjusted p value after Benjamini and Hochberg correction and mixed model ANOVA analyses. Twenty-five proteins were signif-
icantly regulated in PSAPP mice versus wild types. Red highlights depict six common proteins significantly regulated in r-mTBI/hTau/PSAPP mice. List of
proteins in italics represents proteins that also demonstrated significant interaction between genotype and aging. Heat map depicts upregulated levels in blue
and downregulated levels in red. MPA¼master protein accessions.
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et al., 2012, 2014; Ojo et al., 2015; Mouzon et al.,
2018c). This indicates that the anatomical correlates
responsible for the early neurobehavioral changes in
our model may be attributed to subtleties in molecular
responses that cannot be otherwise detected by tradi-
tional gross histopathological analyses.
In this study, we focused our omic analyses within
each specific group (i.e., TBI or sham animals) by creat-
ing a dataset of proteomic responses to injury or normal
aging over multiple extended timepoints postexposure.
This enabled us to identify common and unique proteins
significantly modulated in shams and/or injured groups.
Within the hippocampus, we identified 30 proteins
unique to the TBI group only, and these were changing
over multiple timepoints postinjury. These class of pro-
teins included cytoskeletal proteins, downstream signal-
ing proteins, cell adhesion proteins, mitochondrial-
related proteins, synaptic proteins, glial-associated pro-
teins, and transporter/ion channel proteins. In addition,
injured mice also showed a lack of age-related change in
17 proteins that were unique to and significantly altered
in sham mice, indicating a suppression or dysregulation
in normal age-related processes which may drive patho-
logical aging. These classes of proteins included calcium-
associated and cytoskeletal proteins, SNARE proteins,
kinase enzymes, proteins involved in bioenergetics, and
ubiquitin proteasome-related proteins. The top scoring
diseases and biofunctions (i.e., those most significantly
altered between sham and injured mice) included exocy-
tosis, paired-pulse facilitation of synapse, engulfment of
cells, concentration of ATP, neurodegeneration, synaptic
depression, and formation of vesicles. The top canonical
pathways included PI3K/AKT signaling, protein kinase
A signaling, and PPARa/RXRa activation. These find-
ings implicate pathophysiological responses involving
impaired energy metabolism, clearance mechanisms, neu-
rotransmitter and intracellular signaling, glial cell dys-
function, and diminished neurotrophic support after
injury within the hippocampus. Our interrogation of
the cortex revealed 47 proteins that were changing in
the r-mTBI group compared with the sham controls
over time. They can be categorized mainly as filament
and cytoskeletal proteins, synaptic plasticity proteins,
chaperone proteins, nuclear proteins, synaptic vesicle
proteins, cell adhesion molecules, kinase enzymes, and
mitochondrial proteins involved in energy metabolism.
Table 4. List of Significantly Modulated Proteins From the Cortex of hTau Mice Compared With Wild-Type Littermate Controls.
WILDTYPE MICE hTau MICE 
M.P.A Descripon P Value 9 Mos 15 Mos 9 Mos 15 Mos 
P61922 4-aminobutyrate aminotransferase, mitochondrial  0.032 -0.073 -0.492 0.197 -0.598 
P46660 Alpha-internexin  0.032 0.006 -0.306 -0.012 -0.553 
P05201 Aspartate aminotransferase, cytoplasmic  0.012 -0.188 -0.419 0.110 -0.473 
P02301 Histone H3.3C* 0.013 -0.024 -0.208 0.588 -0.270 
P62806 Histone H4* 0.023 -0.105 -0.441 0.431 -0.515 
Q7TSJ2 Microtubule-associated protein 6  0.033 -0.055 -0.385 0.341 -0.210 
P10636 Microtubule-associated protein tau  0.000 0.162 0.111 3.820 3.633 
P13595 Neural cell adhesion molecule 1  0.027 -0.067 -0.072 -0.218 -0.277 
Q8VDN2 Sodium/potassium-transporng ATPase subunit -1  0.019 -0.038 0.060 -0.076 -0.109 
Note. Data depict least squared mean values generated after logarithmic transformation of normalization abundance ratio data from each genotype group.
p value represents FDR-adjusted p value after Benjamini and Hochberg correction and mixed model ANOVA analyses. Nine proteins were significantly
regulated in hTau versus wild-type mice. Red highlights depict two common proteins significantly regulated in r-mTBI/hTau/PSAPP mice. List of proteins with
asterisks represents proteins that also demonstrated significant interaction between genotype and aging. Heat map depicts upregulated levels in blue and
downregulated levels in red. MPA¼Master protein accessions.
Figure 8. Venn Diagram Depicting Overlap Between Proteins
Changing Over Time in r-mTBI (C57BL/6J Mice), Tau (hTau Mice),
and Amyloid (PSAPP Mice) Models. Totally, 116 proteins were
significantly changing in the injury group, 25 proteins in the amyloid
model, and 9 in the tau model over time. Only six proteins over-
lapped between injury and amyloid models, while two overlapped
between injury and tau models.
r-mTBI¼ repetitive mild traumatic brain injury.
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We also observed that 32 significant proteins uniquely
changing with age in sham mice did not show any signif-
icant changes in injured mice with aging. These classes of
proteins include microglia/macrophage inhibitory pro-
tein factors, plasma membrane and cytoskeletal proteins,
antioxidant proteins, synaptic proteins, growth factors,
and proteins involved in energy metabolism. We
employed an antibody-based approach to validate our
findings for three different proteins that were highly
abundant in the tissue and detectable by ELISA
method, which confirmed similar trends in some of the
groups assessed. It is worthy of note that there was a
discrepancy in our validation attempt for HSP 90 by
ELISA method, which showed changes in opposite direc-
tions by TMT versus ELISA, although changes were
both significant over the timepoints of analyses by
ANOVA. The reason behind these differences is
unknown. We attribute these to issues surrounding the
lack of sensitivity of the ELISA detection method, age of
samples at validation with ELISA and stability of HSP
90 proteins, or possibility of sample degradation due to
multiple freeze thaw cycles (up to 2 cycles). It is also
worthy of note that we confirmed, in our TMT experi-
ments, the increase in levels of our transgene products
(e.g., hTau and hAPP) from the cortices/hippocampi of
our models of tauopathy and amyloidosis at different
ages and also noted TBI-related markers (e.g., glial fibril-
lary acidic protein [GFAP]) previously shown in our his-
topathological studies (Mouzon et al., 2012, 2014, 2018c)
was also confirmed in our TMT experiments.
IPA generated a list of diseases/biofunctions signifi-
cantly altered between injured and sham mice, some of
which included endocytosis, myelination, engulfment of
cells, neurodegeneration of axons, migration of neuro-
glia, clathrin-mediated endocytosis, axonogenesis, and
receptor-mediated endocytosis. The top three canonical
pathways include protein kinase A signaling, protein
GnRH signaling, and B cell receptor activation. Our pro-
teomic profiles of the cortical tissue implicate a complex
and wide array of pathophysiological responses after
injury, possibly involving alterations in synaptic func-
tion, clearance mechanism, energy metabolism and mito-
chondrial function, microglial/immune dysfunction,
axonal/cytoskeletal damage, oxidative stress, and dys-
function in neurotrophic, hormonal, and downstream
intracellular signaling processes. Because we have used
whole cortical regions for these proteomic experiments,
it is possible that our TBI-dependent profiles in injured
mice may be diluted, due to our injury being adminis-
tered at the midline, beneath the parietal cortex. In
Figure 9. Graphic Summary of the Class of Proteins and Impaired Functions Observed in the r-mTBI, Tau, and Amyloid Models.
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parallel plasma biomarker studies from the same mice
used in this model, we identified 31 proteins significantly
changing in the r-mTBI animals over time, and, when
compared with changes observed over time in sham ani-
mals, 13 proteins of these were unique to the TBI mice
(Ojo et al., 2018). The top pathways significantly modu-
lated by these unique TBI-dependent changes were liver
X receptor and retinoid X receptor (LXR/RXR) activa-
tion, production of nitric oxide (NO) and reactive oxygen
species (ROS) and complement systems. Due to the
chronic timepoints selected for these studies and the
mild nature of our injuries, there was no direct overlap
in proteins in the blood and brain, as utility of brain-
derived proteins in the blood is more prominent at
acute timepoints. Nonetheless, due to the alterations in
RXR activation in the hippocampus of our TBI mice and
blood samples, including immune-related changes typi-
fied by activation of complement systems in the blood
and alterations in microglia/macrophage inhibitory fac-
tors and B cell receptor activation in the cortex, we can
surmise that there is a consistent overlap in these patho-
genic processes in the blood and brain that may be inter-
rogated as a putative biomarker of r-mTBI-mediated
neurodegeneration. However, further validations studies
will be needed to confirm this.
There have been few previous studies employing pro-
teomic approaches in preclinical models of mTBI, partic-
ularly those that have explored chronic timepoints
postinjury. A recent study using isobaric tags for relative
and absolute quantitation (iTRAQ)-based proteomic
approach in r-mTBI (3 hits) rats using a metallic
pendulum-striker at 1, 7, and 180 days post-TBI demon-
strated 237 proteins significantly changing between con-
trol and r-mTBI mice, with a prominent role of
upregulation in cAMP signaling pathway (Song et al.,
2018). Other biological activities, such as myelination
of axons, cell adhesion signaling, autophagic clearance,
microtubule depolymerization, and neurodevelopment of
the brain, were also observed. Another study used a
microwave and magnetic (M2) proteomics approach in
2-month-old mice exposed to a single closed skull
impact mouse model using a closed cortical injury
device (2 mm depth and 4.5m/s) that closely resembles
our experimental model used herein (Evans et al., 2014).
The authors collected brain tissue at 1, 7, 30 and 120 days
postinjury and reported significant changes in myelin
cytoskeletal and neurofilament proteins, antioxidant
enzymes, proteins involved in bioenergetics, and neuro-
trophic factors in the ipsilateral brains of injured mice up
to 30 days postinjury, and this correlated with motor
abnormalities. It is noteworthy that this model demon-
strated evidence of neuron loss and edema, indicating
that it is a more severe model than our mild(TBI).
Nonetheless, proteomic profiles in injured mice from
this study and ours appeared to show a large degree of
overlap. In another proteomics study, using rats exposed
to closed cortical injury, the authors revealed mitochon-
drial fraction proteins oxidatively modified in the cortex
and hippocampus after injury (Opii et al., 2007).
Although they also used a more severe model compared
with ours, they likewise confirmed early significant
changes in several proteins involved in energy metabo-
lism in both brain regions analyzed after 3 hr postinjury.
Even though no chronic timepoints were examined in this
study, their work nevertheless supports the early involve-
ment of dysfunctional mitochondrial bioenergetics in
TBI which is known to precipitate a host of different
responses such as oxidative stress, calcium dis-
homeostasis, excitotoxicity, and ATP depletion (Opii
et al., 2007). Another model that explored effects of
fluid percussion (moderate) injury in rat cortical tissue
48 hr after injury using 2D gel electrophoresis and MS/
MS analysis also reported significant changes in mito-
chondrial proteins associated with energy metabolism,
cytoskeletal proteins, hormonal signaling receptors, and
synaptic proteins (Ding et al., 2015).
Quantitative TMT proteomic studies have also been
conducted in single low-intensity blast (mTBI) injury
studies at 2 and 24 hr, and 7 and 30 days postinjury
(Song et al., 2019). Animals revealed mitochondrial and
axonal ultrastructural changes. Remarkable dynamic
changes in 2,216 proteins and 459 phosphorylated pro-
teins at variety of timepoints postinjury were observed.
The key canonical pathways disrupted included mito-
chondrial dysfunction, oxidative stress, and axonal/cyto-
skeletal/synaptic dysregulation. Particularly with respect
to proteomic changes in mitochondria dysfunction,
altered fission/fusion dynamics, reduced mitophagy,
diminished oxidative phosphorylation, and compensated
respiration-relevant enzymatic activities were thought to
underlie these dysfunctions, and these changes were very
prominent at 7 and 30 days postinjury. In another
LC-MS/MS blast-induced mTBI study examined acutely
after injury, using isobaric mass tags for relative protein
quantification, alterations were observed in axonal and
synaptic proteins associated with cortical cytoskeleton
organization, and synaptic vesicle exocytosis (Chen
et al., 2018). Microtubule-associated protein 1B, neuro-
filaments, stathmin, synaptotagmin I, myelin basic pro-
tein, calcium-calmodulin-dependent protein kinase, and
actin binding proteins were the most significantly regu-
lated proteins notably observed in blast versus sham
mice. Although these findings were conducted in different
mTBI models at more acute timepoints compared with
ours, they all appear to demonstrate some similar threads
of pathobiological changes that may occur in continuum
over time, albeit to a different degree in different models
and TBI paradigms.
The translational significance of these preclinical find-
ings cannot yet be confirmed, as there have been no
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proteomic approaches in postmortem brain tissue from
human mTBI. Only severe injuries such as those investi-
gating pericontusional (penumbra) regions following TBI
have been conducted, and the authors reported evidence
of altered cytoskeletal architecture, oxidative stress/
damage, depletion of antioxidant-glutathione, dysfunc-
tion of mitochondria, and synaptic loss (Harish et al.,
2015). Although this human study was conducted at an
acute timepoint following a more severe injury paradigm,
the overlap with some of the molecular responses identi-
fied in our model suggests that these processes may be
common responses even across different types of injury
and may thus offer novel insights into TBI pathobiology
in general.
Cortical Proteomic Profiles in Models of Tau and
Amyloid Pathology
At the outset of this study, we hypothesized that compar-
isons of the detailed time lines of proteomic responses
following r-mTBI and in models of amyloidosis and tau-
opathy would identify underlying pathobiological mech-
anisms common to both pathobiological events.
However, during the length of this study, we observed
from our neuropathological studies a lack of amyloid
and tau pathology in our 5-hit r-mTBI model following
investigations up to 24 months postinjury (see Mouzon
et al., 2012, 2014, 2018c). We thus continued our inves-
tigations by using our proteomic platform to further
pursue and explore the proteomic responses and any
indicators of overlap or distinction between these differ-
ent models.
First, the PSAPP mice are reported to show normal
acquisition in the performance of cognitive tasks between
6 to 9 months when neuropathology is minimal.
However, by 15 to 17 months when the amyloid pathol-
ogy is widespread, there is a progressive age-related
decline in water maze learning and corresponding work-
ing memory when compared with young 5- to 7-month-
old mice (Holcomb et al., 1999; Arendash et al., 2001).
The hTau mice develop tau pathology consistent with
human disease (Andorfer et al., 2003). The distribution
and pathology of hyperphosphorylation, aggregation of
paired helical filaments, and neurofibrillary tangles in
these mice develops in an age-dependent manner and is
evident 9 to 15 months of age (Andorfer et al., 2003;
Andorfer, 2005; Polydoro et al., 2009). Decline in recon-
solidation of object-recognition memory and spatial
learning and memory has been reported from 12 month
old (Polydoro et al., 2009).
Our analyses at 3, 9, and 15 months of age were
designed to capture pre, peri, postonset of neurological
damage in both models. The 25 proteins significantly
changing between PSAPP and wild-type littermates
(19 by genotype, 6 with age and genotype) suggest
amyloid-dependent alterations in mitochondrial bioener-
getics, neurotransmission, cell signaling, vesicular func-
tion, and aberrant cytoskeletal reorganization. In the
hTau model, the seven proteins that significantly altered
compared with wild-type mice and four with age and
genotype interaction indicate pathogenic tau-dependent
changes in mitochondrial bioenergetics, protein machin-
ery, cell signaling, cytoskeletal reorganization, and
axonal transport. In parallel studies from the plasma,
we identified 18 plasma proteins significantly changing
in our PSAPP mice and 19 proteins changing in our
hTau mice compared with counterpart wild-type litter-
mates/controls with aging (Ojo et al., 2018). The top reg-
ulated canonical pathways identified by IPA in PSAPP
plasma samples with aging compared with their wild-type
littermates included production of NO and ROS, acute
phase response signaling, and LXR/RXR activation. In
hTau plasma, we identified coagulation system, LXR/
RXR activation, and production of NO and ROS signif-
icantly modulated with aging compared with wild-type
controls. No direct overlap was observed in proteins
changing in the blood and brain. As both models are
driven by the insertion of a transgene and or mutation,
the unique pathogenic changes observed in the plasma
with aging may thus indicate the consequence of tau
and amyloid pathologies, which may be used as a correl-
ative biomarker of these processes in the blood.
However, validation of these processes in human studies
is needed to corroborate our findings.
Previous proteomic approaches in animal models and
using human brains exhibiting tau and amyloid patholo-
gies confirm some of our findings. Preceding studies using
the PSAPP mouse model compared with age-matched
controls demonstrated increased levels of protein oxida-
tion of metabolic enzymes and cytoskeletal proteins
(Abdul et al., 2008; Sultana et al., 2011), coupled with
significant reductions in proteins involved in energy
metabolism such as glyceraldehyde-3-phosphate dehy-
drogenase and enolase (Abdul et al., 2008; Robinson
et al., 2011). In addition, redox proteomics studies in
this model also revealed an age-related significant alter-
ation in proteins involved in mitochondrial bioenergetics
(Swomley and Butterfield, 2015). In a recent study
involving 8-month-old 5xFAD mice (where amyloid
pathology is observed as early as 2 to 3 months), IPA
of proteins identified to be significantly modulated in the
hippocampus of Tg mice versus controls revealed mito-
chondrial dysfunction and Gi-mediated intracellular sig-
naling which is involved with the inhibition of cAMP
production from ATP and reduction in neuronal excit-
ability and neurotransmitter release (Neuner et al., 2017).
In 3xTgAD mice, significant alterations were reported
(postonset of amyloidosis) in proteins associated with
synaptic plasticity, neurite outgrowth, and microtubule
dynamics (Martin et al., 2008). Intracerebral injections
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of Ab (1–40) have also been shown to decrease levels of
proteins linked with the production of ATP and cytoskel-
etal integrity (Shi et al., 2011). Ab (1-42) injections into
the nucleus basalis magnocellularis of rodents also
showed significant changes to proteins such as glutamine
synthetase, beta-synuclein, 14-3-3 zeta, phosphoglycerate
mutase 1, pyruvate dehydrogenase, and glyceraldehyde-
3-phosphate dehydrogenase in the cortex, nucleus basalis
magnocellularis, and hippocampus (Boyd-Kimball et al.,
2005). In vitro studies exploring the effects of different Ab
species exposed to cell cultures have also corroborated
some of these molecular findings using targeted and unbi-
ased proteomic approaches. For example, exposure of
Ab (25–35), Ab (1–40) or oligomeric Ab (1–42) to neu-
ronal cell cultures results in the production of free radi-
cals/ROS/protein carbonyls (Hensley et al., 1994; Harris
et al., 1995; Yatin et al., 1999, 2000; Butterfield and
Boyd-Kimball, 2004), oxidation of proteins associated
with energy metabolism and cytoskeletal function
(Boyd-Kimball et al., 2005; Sultana et al., 2006a,
2006b, Sultana and Butterfield, 2009), decreased levels
of metabolic enzymes, and increased chaperone proteins
(F€oldi et al., 2011). Immortalized microglial cells exposed
to Ab (25–35) also demonstrated downregulation of met-
abolic enzymes, redox proteins, and chaperone proteins
(Di Francesco et al., 2012). These together implicate a
pivotal role in mitochondrial bioenergetics, synaptic plas-
ticity, and protein clearance mechanisms in association
with amyloidogenesis.
Very few proteomic studies have been conducted in
tau transgenic mice. One study used a NSE-htau23
model that displays NFT deposition (Chang et al.,
2013). Proteomic analyses at 6 and 12 months of age
identified downregulation of glutathione S-transferase
P1 and carbonic anhydrase II with the progression of
NFT pathology, upregulation in secerin-1 and V-type
proton ATPase subunit E 1 (ATP6VE1) in early stages,
and downregulation in the chronic stages of tauopathy.
As with our analyses, these changes suggest a unique and
important role in dysfunctional energy metabolism in
association with age-related tauopathy.
A plethora of proteomics studies conducted on human
tissue exhibiting tauopathy and amyloidosis also validate
our preclinical studies. Cytoskeletal protein phosphory-
lation enzyme Pin-1 and microtubule-associated protein,
b-tubulin, were significantly reduced, while glycolytic
enzymes and molecular chaperone HSP 70 were signifi-
cantly increased in autopsy brains (Sultana et al., 2007).
Similar changes have been reported in detergent insoluble
fractions of AD brains with tau/amyloid pathology
showing alteration in proteins involved in energy
metabolism (Woltjer et al., 2005). Positron emission
tomography scanning supports these finding implicating
deficiency in energy metabolism, as deficits in cerebral
glucose uptake is a typical feature observed in the
brains of patients with tauopathy and amyloidosis
(Watson and Craft, 2004). A redox proteomic approach
of human brain tissue with pathologically confirmed tau
and amyloid pathology also identified oxidation of a
variety of proteins and oxidative stress as a driving
force in the neuropathological sequelae to tauopathy
and amyloidosis (Castegna et al., 2002a, 2002b;
Butterfield and Castegna, 2003; Castegna et al., 2002c;
Castegna et al., 2003; Sultana et al., 2006b). In another
study, Begcevic et al. (2013) used a semiquantitative pro-
teomic analyses to interrogate human brain tissue with
confirmed tau and amyloid pathology and age-matched
controls. The authors reported alterations in metabolic
processing of amyloid precursor protein, diminished oxi-
dative phosphorylation, dysfunction in calcium homeo-
stasis and mitochondrial function, and aggregation of
Ab. Among the biological activities altered, cellular and
primary metabolic processes, vesicle-mediated transport,
oxidative phosphorylation, and positive regulation of
ubiquitin activity were highly significant.
Thus, it appears that from our findings herein and our
selection of reports from in vitro animal and human stud-
ies, a common theme emerges regarding the main path-
ophysiological changes in the brains exhibiting tau- and
amyloid-driven pathological lesions, which can be cate-
gorized by significant changes in mitochondrial function,
energy metabolism, signal transduction, synaptic func-
tion, structural cytoskeletal organization, proteasome
function, and protein clearance mechanisms (Swomley
and Butterfield, 2015).
Overlap in Brain Proteomic Profiles in Models of r-mTBI,
Tauopathy, and Amyloidosis. When we investigated the
molecular comparisons between r-mTBI and two
unique models of amyloidosis and tauopathy in the
cortex, we found only eight total proteins that were
highly statistically significant and common, namely
ADP/ATP translocase 2, CAMKII, hemoglobin subunit
a, hexokinase-1, NADH-ubiuinone oxidoreductase, and
spectrin alpha chain, nonerythrocytic 1, alpha-internexin,
and neural cell adhesion molecule 1. These proteins were
involved in mitochondrial bioenergetics, aberrant cyto-
skeletal reorganization, and alterations in intracellular
signaling cascades and transduction. Our findings osten-
sibly support the notion that the sequelae of events fol-
lowing TBI-mediated neurodegeneration and in
transgenic models of disease-undefined “amyloidosis”
(PSAPP mouse) and “tauopathy” (hTau mouse) only
show very subtle similarities in molecular responses,
suggesting a more complex picture of the proteomic
response, with likely distinct and separate neurodegener-
ative processes occurring following
TBI-neurodegeneration and tau/amyloid pathogenesis.
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Limitations
As a common caveat inherent to all proteomic studies, we
acknowledge the possibilities of false negative results,
inaccuracies in protein identification criteria, and possi-
ble issues surrounding the sensitivity of our approach for
identifying low abundant proteins. This is primarily
attributed to biological and technical limitations that
are inherent to current approaches that are unable to
yield whole coverage of the full proteome (de Godoy
et al., 2006; Cox and Mann, 2011). As such, caution
should be used when interpreting any proteomic dataset.
Several reasons may explain these caveats. For example,
peptides with a low abundant protein may elute at the
same time with those from a highly abundant protein
and, thus, will be omitted for sequencing by our MS pro-
cedure. Also, unique peptides generated by trypsin diges-
tion may possess certain qualities that preclude their
adequate ionization, making them incompatible for
detection by MS. On the other hand, peptides that
ionize well may not be unique and, thus, will not be reli-
ably attributed to a particular protein (de Godoy et al.,
2006). It is worth mentioning that we have tried to avoid
or minimize any issues surrounding false positive protein
identifications by using a very strict FDR cutoff point of
0.01 in this study. In addition, the use of homogenates
from entire brain regions may result in masking of more
subtle molecular responses that might be cell specific or
primarily subcellular in nature.
The use of a sample size of four/group in this study
warrants discussion. We selected this sample size based
on our literature search of previous proteomic experi-
ments (mentioned earlier) reporting a similar group
size. It is worthy of note that our model has been well
characterized and demonstrates consistent pathological
and behavioral phenotypes (Mouzon et al., 2012, 2014,
2018c; Ojo et al., 2015), which is further supported by the
large number of unique and statistically significant pro-
teins identified in the mTBI group. While a larger sample
size or higher powered study of larger cohorts merit addi-
tional investigation, this work nonetheless supports our
proof-of-concept that an unbiased proteomics approach
involving a detailed time line of molecular events in pre-
clinical models of disease can serve as an invaluable tool
to explore putative changes to proteins and molecular
pathways significantly altered during the pathogenesis
of disease.
We also acknowledge from hindsight of this study
(owing to the lack of tau pathology and amyloid plaques
in our TBI model—see Mouzon et al., 2012, 2014, 2018c)
that the wild-type mouse model we have chosen may not
represent the best platform for exploring how r-mTBI
contributes to tau or amyloid pathogenesis. Also, Ab42
protein is not detectable in our wild-type TBI mice using
commercially available ELISA’s, and murine Ab40
(which can be detected) does not show any change after
injury (Mouzon et al., 2014, 2018c). Thus, our reports
can focus only on the sequelae of events after TBI (i.e.,
time-dependent molecular changes) as they compare/
relate to molecular changes in the models of tauopathy/
amyloidosis.
Our TBI work in hTau mice have observed augmen-
tation of tauopathy in aged rather than young animals
(Ojo et al., 2013; Mouzon et al., 2018a, 2018b) and also
with a more chronic mTBI paradigm (Ojo et al., 2016a),
suggesting that the ability to demonstrate TBI-dependent
proteinopathy might be dependent on several factors
such as age at injury, frequency of hits, and use of rele-
vant humanized (nonmutant) models (Ojo et al., 2016b).
Despite the lack of tau and amyloid pathology in our
wild-type TBI model, we have previously reported path-
ological changes such as axonal injury, gliosis, and white
matter degeneration, along with spatial memory deficits
from 24 hr to 24 months postinjury (Mouzon et al., 2012,
2014, 2018c), which are all relevant to the complex path-
obiological mechanisms involved in TBI-mediated neuro-
degeneration. We thus consider that our findings are still
vital to present to the TBI community, and we are con-
fident that with the development of better models of TBI
exhibiting relevant proteinopathies, our future work will
be able to closely address this elusive interrelationship at
the molecular level.
Another limitation of our study design was the lack of
statistical comparison between our TBI and amyloidosis/
tauopathy models and also the timepoints/ages in our
TBI versus tau/amyloid transgenic groups not included
that precluded direct comparisons at 6 and 12 months of
age. This was due to our initial study design for our TMT
workflow, where we ran samples in batches consisting of
(nonnormalized) TBI and sham groups alone in a single
10-plex experiment, or separately Tau or PSAPP versus
their wild-type counterparts, in a single 6-plex study.
Given this limitation, we were only able to conduct our
comparative statistical analyses focusing on sham- and
TBI-“specific” changes over the five multiple timepoints
investigated and also naı¨ve wild-type control, tauopathy,
and amyloidosis-dependent changes over the three
chosen ages, looking for unique overlaps in the trajectory
of temporal profiles. A better approach from hindsight
would have been to include a reference sample in all
plexes for normalization of each sample, to enable gen-
eration of normalized ratio’s and direct comparison of
group differences between different experiments.
Although we have not explored the impact of expo-
sure to five separate anesthesias on molecular changes in
the brain, we do not anticipate major differences between
r-sham and naı¨ve unexposed mice. Nonetheless, we sug-
gest that inclusion of a naı¨ve group in future studies
would have been beneficial to address this issue.
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Conclusion
This work was designed to investigate the detailed
time-dependent molecular events after r-mTBI, and
their overlap with the pathogenic events in animal
models of amyloidosis and tauopathy. Herein, we detail
a detailed time line of changes following r-mTBI and in
tau/amyloid-driven transgenic animal models. We chose
to investigate timepoints encompassing pre-, peri-, and
post-“onset” of the cognitive and pathological pheno-
types. At the outset, we observed a lack of amyloid and
tau pathology in our injury model.
In our studies, we report our molecular library of
changes from these studies and demonstrate mainly dis-
tinct response to TBI in our injury model compared with
models of amyloidosis and tauopathy, signifying a dis-
tinct TBI-mediated neurodegeneration, and a very com-
plex proteomic response in both cases. This work also
suggests that other factors are needed to drive the tau
and amyloid pathologies observed in the small percent-
age of patients exposed to repetitive concussive injuries.
Nonetheless, the significantly regulated pathways we
have identified in our TBI model (e.g., PI3K/AKT and
protein kinase-A signaling, PPARa/RXRa activation,
GnRH signaling and B cell receptor signaling) may
serve as unique targets for therapeutic intervention
against the consequences of r-mTBI.
Given the lack of amyloid and tau pathology in our
wild-type injury model possibly owing to the intrinsic
properties of murine Ab, we were unable to explore the
impact of r-mTBI on risk for AD. We therefore recognize
that more studies need to be conducted in relevant
models, such as the humanized Tau and humanized
APP knock in mice to investigate the contribution of
these pathogenic mechanisms as relevant factors in the
population of TBI patients at risk of developing AD in
later life. Although beyond the scope of this current
study, we acknowledge that further work will be needed
to confirm changes in proteins implicated in significantly
modulated pathways, their messenger RNA signals, and
cellular origin, including validation of our findings in
autopsy brain tissue to confirm human relevance. We
are pursuing these studies in our current work.
Summary
• Thirty hippocampal and 47 cortical proteins were sig-
nificantly modulated over time in the r-mTBI com-
pared with sham mice, implicating PI3K/AKT,
protein kinase A, PPARa/RXRa activation, GnRH,
and B cell receptor signaling.
• In PSAPP mice, 19 proteins significantly changed in
the cortex, but only 7 proteins in hTau mice compared
with wild-type littermates.
• Overlap between r-mTBI model and the PSAPP/hTau
models showed a fairly small coincidental change
involving eight significantly regulated proteins, sug-
gesting a very distinct TBI neurodegeneration com-
pared with tau or amyloid pathogenesis.
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